IPO registrations (S-1, F-1) · Registrants
Arcus Biosciences, Inc.
- SEC CIK
- 1724521 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2018-02-16, last 2018-03-09; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2018-03-16; declared effective 2018-03-14
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 3928 POINT EDEN WAY, Hayward, CA 94545
- EIN
- 47-3898435
- Ticker
- RCUS (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Arcus Biosciences, Inc. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2018-03-09)
- Final price
- $15.00 per share, within the range (424B4 filed 2018-03-16, an initial public offering)
- Shares sold
- 8,000,000
- Gross proceeds
- $120,000,000 before underwriting discounts and any over-allotment option
- Listing
- NYSE under the symbol RCUS
- Lead underwriters
- Citigroup; Goldman Sachs; Leerink Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ARCUS BIOSCIENCES, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: ARCUS BIOSCIENCES, INC. EXACT (EIN (EXACT))
- SEC filer: Arcus Biosciences, Inc. EXACT (CIK (EXACT))
- Person page: David L Lacey Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: David W Beier Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Juan C Jaen Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-02-16 | S-1 | S-1 (registration) | Arcus Biosciences, Inc. | 0001193125-18-048700 ↗ |
| 2018-03-05 | S-1/A | S-1/A (amendment) | Arcus Biosciences, Inc. | 0001193125-18-069517 ↗ |
| 2018-03-09 | S-1/A | S-1/A (amendment) | Arcus Biosciences, Inc. | 0001193125-18-077549 ↗ |
| 2018-03-14 | S-1MEF | S-1MEF (added securities) | Arcus Biosciences, Inc. | 0001193125-18-082751 ↗ |
| 2018-03-14 | EFFECT | EFFECT (declared effective) | Arcus Biosciences, Inc. | 9999999995-18-000599 ↗ |
| 2018-03-16 | 424B4 | 424B4 (final prospectus) | Arcus Biosciences, Inc. | 0001193125-18-084508 ↗ |
| 2019-04-25 | EFFECT | EFFECT (declared effective) | Arcus Biosciences, Inc. | 9999999995-19-000834 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-03-09 | S-1/A | registration statement | $13.00–$15.00 | 7,100,000 | - | NYSE RCUS | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2018-03-16 | 424B4 | final prospectus | $15.00 | 8,000,000 | $120,000,000 | NYSE RCUS | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alphabet Inc. | TenPercentOwner | 4 | 2018 | ||
| BEIER DAVID W | Director | 2 | 2018–2019 | person page Fuzzy | |
| Chan Steven | Officer | See Remarks | 2 | 2018–2019 | |
| Column Group II GP, LP | TenPercentOwner | 2 | 2018 | ||
| COLUMN GROUP II, LP | TenPercentOwner | 2 | 2018 | ||
| FALBERG KATHRYN E | Director | 14 | 2018–2026 | ||
| GOEDDEL DAVID V | TenPercentOwner | 2 | 2018 | ||
| GV 2016 GP, L.L.C. | TenPercentOwner | 2 | 2018 | ||
| GV 2016 GP, L.P. | TenPercentOwner | 2 | 2018 | ||
| GV 2016, L.P. | TenPercentOwner | 2 | 2018 | ||
| GV 2017 GP, L.L.C. | TenPercentOwner | 2 | 2018 | ||
| GV 2017 GP, L.P. | TenPercentOwner | 2 | 2018 | ||
| GV 2017, L.P. | TenPercentOwner | 2 | 2018 | ||
| Hadley Harbor Master Investors (Cayman) II L.P. | TenPercentOwner | 2 | 2018 | ||
| Jaen Juan C. | Director,Officer; Director,Officer,TenPercentOwner; Officer | President | 35 | 2018–2026 | person page Fuzzy |
| Jarrett Jennifer | Director; Director,Officer; Officer | Chief Operating Officer; See Remarks | 40 | 2018–2026 | |
| KANEKO YASUNORI | Director; Director,TenPercentOwner | 12 | 2018–2026 | ||
| Kutzkey Tim | TenPercentOwner | 2 | 2018 | ||
| PONOI CAPITAL, LP | TenPercentOwner | 2 | 2018 | ||
| Ponoi Management, LLC | TenPercentOwner | 2 | 2018 | ||
| ROSEN TERRY J | Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer | 33 | 2018–2026 | |
| Svennilson Peter | TenPercentOwner | 2 | 2018 | ||
| Hege Kristen | Director | 3 | 2018–2019 | ||
| Hemrajani Rekha | Officer | See Remarks | 2 | 2019 | |
| Grossman William | Officer | Chief Medical Officer | 12 | 2019–2021 | |
| Barker Jason | Officer | See Remarks | 3 | 2019–2020 | |
| Ribas Antoni | Director | 12 | 2019–2026 | ||
| Machado Patrick | Director | 9 | 2019–2026 | ||
| Lacey David L. | Director | 9 | 2020–2026 | person page Fuzzy | |
| Parsey Merdad | Director | 1 | 2020 | ||
| GILEAD SCIENCES INC | TenPercentOwner | 5 | 2020–2025 | ||
| Goeltz II Robert C. | Officer | Chief Financial Officer | 22 | 2020–2026 | |
| PERLMAN ANDREW J | Director | 8 | 2020–2026 | ||
| Tang Carolyn C. | Officer | General Counsel | 17 | 2020–2026 | |
| Quigley Michael | Director | 1 | 2021 | ||
| Lambert Nicole | Director | 7 | 2021–2026 | ||
| Higgins Linda Slanec | Director | 1 | 2021 | ||
| Nuyten Dimitry SA | Officer | Chief Medical Officer | 8 | 2022–2024 | |
| Azoy Alexander | Officer | Chief Accounting Officer | 18 | 2023–2026 | |
| Mercier Johanna | Director | 1 | 2024 | ||
| Berger Dietmar | Director | 1 | 2025 | ||
| Markus Richard | Officer | Chief Medical Officer | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ARCUS BIOSCIENCES, INC. | CA | State business registries | name and state |
| Plan sponsor | ARCUS BIOSCIENCES, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Patent assignee | Arcus Biosciences, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | Arcus Biosciences, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Arcus Biosciences, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | ARCUS BIOSCIENCES, INC. | EIN (EXACT) | ||
| Person page | David L Lacey | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | David W Beier | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Juan C Jaen | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CymaBay Therapeutics, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health